SpringerLink
Log in

Pitavastatin Reduces Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Ligands in Hypercholesterolemic Humans

  • Original Article
  • Published:
Lipids

Abstract

The aim of this study was to determine the impact of pitavastatin on low-density lipoprotein cholesterol (LDL-C) and lectin-like oxidized LDL receptor-1 (LOX-1) in patients with hypercholesterolemia. Twenty-five hypercholesterolemic patients (8 male, 17 female; age 66 ± 13, 21–80 years) who had not received anti-dyslipidemic agents and had LDL-C levels of more than 160 mg/dL were examined. Biochemical factors were measured at baseline and after treatment with pitavastatin (2 mg/day) for 6 months. Serum levels of LOX-1 with apolipoprotein B-100 particle ligand and a soluble form of LOX-1 (sLOX-1) were measured by ELISA. All subjects completed the study with no adverse side effects. Total-C (268 ± 26 vs. 176 ± 17 mg/dL), LDL-C (182 ± 21 vs. 96 ± 14 mg/dL), and LOX-1 ligand (867 ± 452 vs. 435 ± 262 ng/mL) were reduced with pitavastatin treatment (P < 0.0001 for each). Significant decreases in triacylglycerols were noted (P < 0.0001), but there were no changes in high-density lipoprotein cholesterol. After 6 months, there were no significant changes in high-sensitivity CRP or soluble LOX-1. At baseline, there were no significant correlations between LOX-1 ligand and either LDL-C or sLOX-1. The decrease in LOX-1 ligand was not correlated with the decrease in LDL-C, but was correlated with the decrease in sLOX-1 (r = 0.47, P < 0.05). In conclusion, pitavastatin therapy had beneficial effects on markers of oxidative stress in hypercholesterolemic subjects. Serum levels of LOX-1 ligand may be a useful biomarker of the pleiotropic effects of statins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Spain)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

LOX-1:

Lectin-like oxidized LDL receptor-1

sLOX-1:

Soluble LOX-1

LDL-C:

Low-density lipoprotein cholesterol

HDL-C:

High-density lipoprotein cholesterol

OxLDL:

Oxidized low-density lipoprotein

CRP:

C-reactive protein

ELISA:

Enzyme-linked immunosorbent assay

TAG:

Triacylglycerol

TC:

Total cholesterol

References

  1. Scandinavian Simvastatin Survival Study (4S) Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344(8934):1383–1389

    Google Scholar 

  2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335(14):1001–1009

    Article  CAS  PubMed  Google Scholar 

  3. Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):7–22

    Article  Google Scholar 

  4. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D (1998) Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98:1487–1494

    CAS  PubMed  Google Scholar 

  5. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE (2001) Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndrome. Circulation 103:1955–1960

    CAS  PubMed  Google Scholar 

  6. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N, Yokoyama M (2001) Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154:87–96

    Article  CAS  PubMed  Google Scholar 

  7. Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, Nath KA, Holmes DR Jr, Lerman A (2001) Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 21:122–128

    Article  CAS  PubMed  Google Scholar 

  8. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, Matsui H, Iguchi A (2001) A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects—the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 155:347–357

    Article  CAS  PubMed  Google Scholar 

  9. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T (1997) An endothelial receptor for oxidized low-density lipoprotein. Nature 386:73–77

    Article  CAS  PubMed  Google Scholar 

  10. Ogura S, Kakino A, Sato Y, Fujita Y, Iwamoto S, Otsui K, Yoshimoto R, Sawamura T (2009) LOX-1: the multifunctional receptor underlying cardiovascular dysfunction. Circ J 73(11):1993–1999

    Article  CAS  PubMed  Google Scholar 

  11. Sato Y, Nishimichi N, Nakano A, Takikawa K, Inoue N, Matsuda H, Sawamura T (2008) Determination of LOX-1-ligand activity in mouse plasma with a chicken monoclonal antibody for ApoB. Atherosclerosis 200(2):303–309

    Article  CAS  PubMed  Google Scholar 

  12. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, JAPAN-ACS Investigators (2009) Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54(4):293–302

    Article  PubMed  Google Scholar 

  13. Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, Nishikawa T, Kodama T, Tada N, Saito Y (2008) Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 201(2):345–352

    Article  CAS  PubMed  Google Scholar 

  14. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Trial Study Group (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373(9670):1175–1182

    Article  CAS  PubMed  Google Scholar 

  15. Inoue N, Okamura T, Kokubo Y, Fujita Y, Sato Y, Nakanishi M, Yanagida K, Kaikino A, Iwamoto S, Watanabe M, Ogura S, Otsui K, Matsuda H, Uchida K, Yoshimoto R, Sawamura T (2010) LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clinical Chemistry (in press)

  16. Liao JK (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96(5A):24F–33F

    Article  CAS  PubMed  Google Scholar 

  17. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD (1990) Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344:160–162

    Article  CAS  PubMed  Google Scholar 

  18. Matsumoto T, Takashima H, Ohira N, Tarutani Y, Yasuda Y, Yamane T, Matsuo S, Horie M (2004) Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. J Am Coll Cardiol 44(2):451–457

    Article  CAS  PubMed  Google Scholar 

  19. Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M (1990) Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 343:531–535

    Article  CAS  PubMed  Google Scholar 

  20. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA (1993) CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268:11811–11816

    CAS  PubMed  Google Scholar 

  21. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D (1996) Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci USA 93:14833–14838

    Article  CAS  PubMed  Google Scholar 

  22. Chen M, Masaki T, Sawamura T (2002) LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 95(1):89–100

    Article  CAS  PubMed  Google Scholar 

  23. Murase T, Kume N, Kataoka H, Minami M, Sawamura T, Masaki T, Kita T (2000) Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol 20(3):715–720

    CAS  PubMed  Google Scholar 

  24. Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, Tanaka M, Ueda A, Kominami G, Kambara H, Kimura T, Kita T (2005) Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 112(6):812–818

    Article  CAS  PubMed  Google Scholar 

  25. Lubrano V, Del Turco S, Nicolini G, Di Cecco P, Basta G (2008) Circulating levels of lectin-like oxidized low-density lipoprotein receptor-1 are associated with inflammatory markers. Lipids 43(10):945–950

    Article  CAS  PubMed  Google Scholar 

  26. Oka K, Yasuhara M, Suzumura K, Tanaka K, Sawamura T (2006) Antioxidants suppress plasma levels of lectin like oxidized low-density lipoprotein receptor-ligands and reduce atherosclerosis in Watanabe heritable hyperlipidemic rabbits. J Cardiovasc Pharmacol 48(4):177–183

    CAS  PubMed  Google Scholar 

  27. Calabro P, Willerson JT, Yeh ET (2003) Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108:1930–1932

    Article  CAS  PubMed  Google Scholar 

  28. Li L, Roumeliotis N, Sawamura T, Renier G (2004) C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 95(9):877–883

    Article  CAS  PubMed  Google Scholar 

  29. Fujita Y, Kakino A, Nishimichi N, Yamaguchi S, Sato Y, Machida S, Cominacini L, Delneste Y, Matsuda H, Sawamura T (2009) Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 55(2):285–294

    Article  CAS  PubMed  Google Scholar 

  30. Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators, Koshiyama H, Taniguchi A, Tanaka K, Kagimoto S, Fujioka Y, Hirata K, Nakamura Y, Iwakura A, Hara K, Yamamoto T, Kuroe A, Ohya M, Fujimoto S, Hamamoto Y, Honjo S, Ikeda H, Nabe K, Tsuda K, Inagaki N, Seino Y, Kume N (2008) Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia. J Atheroscler Thromb 15(6):345–350

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Akiko Ikai, Human Health Sciences, Graduate School of Medicine, Kyoto University, for providing technical assistance.

Conflict of interest statement

We have no any commercial associations that might pose a conflict of interest in connection with this article.

Author information

Authors and Affiliations

  1. Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Seta Tsukinowa, Otsu, Shiga, 520-2192, Japan

    Tetsuya Matsumoto, Hideki Hayashi & Minoru Horie

  2. Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Masatoshi Fujita

  3. Department of Vascular Physiology, National Cardiovascular Center Research Institute, Suita, Japan

    Tatsuya Sawamura, Akemi Kakino, Yuko Sato & Yoshiko Fujita

  4. Laboratory of Immunology, Department of Molecular and Applied Biology, Graduate School of Biosphere Science, Hiroshima University, Hiroshima, Japan

    Haruo Matsuda

  5. Biomarker Science Co., Ltd., Osaka, Japan

    Mamoru Nakanishi & Kagehiro Uchida

  6. Department of Internal Medicine, Jyohoku Hospital, Kyoto, Japan

    Izuru Nakae

  7. Division of Internal Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan

    Hiroshi Kanda

  8. Department of Internal Medicine, Mitsubishi Kyoto Hospital, Kyoto, Japan

    Akira Yoshida

  9. Department of Internal Medicine, Nanto Family and Community Medical Center, Toyama, Japan

    Kunihisa Miwa

  10. Department of Family Medicine, Shiga University of Medical Science, Otsu, Japan

    Kenichi Mitsunami

Authors
  1. Tetsuya Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masatoshi Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tatsuya Sawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akemi Kakino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuko Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshiko Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Haruo Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mamoru Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kagehiro Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Izuru Nakae
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hiroshi Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Akira Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kunihisa Miwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hideki Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kenichi Mitsunami
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Minoru Horie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tetsuya Matsumoto.

About this article

Cite this article

Matsumoto, T., Fujita, M., Sawamura, T. et al. Pitavastatin Reduces Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Ligands in Hypercholesterolemic Humans. Lipids 45, 329–335 (2010). https://doi.org/10.1007/s11745-010-3402-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11745-010-3402-7

Keywords

Search

Navigation